1.Epidemiological characteristics of patients with scabies at a Korean university hospital: a single-center retrospective study
Hye Eun HWANG ; Jae Sim JEONG ; Yang Ree KIM ; Ji young LEE
Journal of Korean Biological Nursing Science 2025;27(1):133-143
		                        		
		                        			
		                        			 This study aimed to establish infection control strategies for preventing the spread of scabies within a single institution by analyzing the epidemiological characteristics of patients diagnosed with scabies. Methods: This was a retrospective descriptive study. The electronic medical records of 430 patients diagnosed with scabies at the dermatology outpatient department of Uijeongbu St. Mary’s Hospital from January 2020 to December 2022 were used to collect data on their characteristics. The subjects were divided into three groups: patients, family of confirmed patients, and healthcare workers. General and epidemiological characteristics were analyzed. Results: The average age was 60.89 ± 22.39 years. The number of days from symptom onset to diagnosis was unknown in many cases (65.3%), although the average was 63.42 ± 64.18 days. Repeated visits after treatment were observed in 193 patients (67.5%), 38 family members of confirmed patients (55.1%), and 35 healthcare workers (46.7%), showing a statistically significant difference (p = .002). The most common place of residence before the visit was home (56.2%), and the most common suspected origin of contagion was the home (38.3%), and the most common category of the suspected contagious person was family (49.6%). Conclusion: Cases of scabies were disproportionately common in women and older adults. The interval from symptom onset to diagnosis was long, and about half of the cases involved itching but no skin lesions. More than one-thirds of cases did not revisit for a follow-up after 2 weeks. In the overall results, unlike previous studies, factors related to home and family were frequently observed as epidemiological characteristics. 
		                        		
		                        		
		                        		
		                        	
2.Combination of Aβ40, Aβ42, and Tau Plasma Levels to Distinguish Amyloid-PET Positive Alzheimer Patients from Normal Controls
Seungyeop BAEK ; Jinny Claire LEE ; Byung Hyun BYUN ; Su Yeon PARK ; Jeong Ho HA ; Kyo Chul LEE ; Seung-Hoon YANG ; Jun-Seok LEE ; Seungpyo HONG ; Gyoonhee HAN ; Sang Moo LIM ; YoungSoo KIM ; Hye Yun KIM
Experimental Neurobiology 2025;34(1):1-8
		                        		
		                        			
		                        			 Alzheimer disease (AD) diagnosis is confirmed using a medley of modalities, such as the detection of amyloid-β (Aβ) neuritic plaques and neurofibrillary tangles with positron electron tomography (PET) or the appraisal of irregularities in cognitive function with examinations. Although these methods have been efficient in confirming AD pathology, the rising demand for earlier intervention during pathogenesis has led researchers to explore the diagnostic potential of fluid biomarkers in cerebrospinal fluid (CSF) and plasma. Since CSF sample collection is invasive and limited in quantity, biomarker detection in plasma has become more attractive and modern advancements in technology has permitted more efficient and accurate analysis of plasma biomolecules. In this study, we found that a composite of standard factors, Aβ40 and total tau levels in plasma, divided by the variation factor, plasma Aβ42 level, provide better correlation with amyloid neuroimaging and neuropsychological test results than a level comparison between total tau and Aβ42 in plasma. We collected EDTA-treated blood plasma samples of 53 subjects, of randomly selected 27 AD patients and 26 normal cognition (NC) individuals, who received amyloid-PET scans for plaque quantification, and measured plasma levels of Aβ40, Aβ42, and total tau with digital enzyme-linked immunosorbent assay (ELISA) in a blinded manner. There was difficulty distinguishing AD patients from controls when analyzing biomarkers independently. However, significant differentiation was observed between the two groups when comparing individual ratios of total-tau×Aβ40/Aβ42. Our results indicate that collectively comparing fluctuations of these fluid biomarkers could aid in monitoring AD pathogenesis. 
		                        		
		                        		
		                        		
		                        	
3.Prediction of Cancer Incidence and Mortality in Korea, 2025
Kyu-Won JUNG ; Mee Joo KANG ; Eun Hye PARK ; E Hwa YUN ; Hye-Jin KIM ; Jeong-Eun KIM ; Hyun-Joo KONG ; Kui Son CHOI ; Han-Kwang YANG
Cancer Research and Treatment 2025;57(2):331-338
		                        		
		                        			 Purpose:
		                        			This study aimed to project cancer incidence and mortality for 2025 to estimate Korea’s current cancer burden. 
		                        		
		                        			Materials and Methods:
		                        			Cancer incidence data from 1999 to 2022 were obtained from the Korea National Cancer Incidence Database, while cancer mortality data from 1993 to 2023 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2025. A joinpoint regression model was applied to identify significant changes in trends, using only the most recent trend data for predictions. 
		                        		
		                        			Results:
		                        			A total of 304,754 new cancer cases and 84,019 cancer deaths are expected in Korea in 2025. The most commonly diagnosed cancer is projected to be thyroid cancer, followed by the colorectal, lung, breast, prostate and stomach cancers. These six cancers are expected to account for 63.8% of the total cancer burden. Lung cancer is expected to be the leading cause of cancer-related deaths, followed by liver, colorectal, pancreatic, stomach, and gallbladder cancers, together comprising 66.6% of total cancer deaths. 
		                        		
		                        			Conclusion
		                        			The increasing incidence of female breast cancer and the rise in prostate and pancreatic cancers are expected to continue. As aging accelerates, cancer commonly found in older adults are projected to rise significantly. 
		                        		
		                        		
		                        		
		                        	
4.Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022
Eun Hye PARK ; Kyu-Won JUNG ; Nam Ju PARK ; Mee Joo KANG ; E Hwa YUN ; Hye-Jin KIM ; Jeong-Eun KIM ; Hyun-Joo KONG ; Kui-Son CHOI ; Han-Kwang YANG ;
Cancer Research and Treatment 2025;57(2):312-330
		                        		
		                        			 Purpose:
		                        			The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2022, with international comparisons. 
		                        		
		                        			Materials and Methods:
		                        			Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2022), with survival follow-up until December 31, 2023. Mortality data obtained from Statistics Korea, while international comparisons were based on GLOBOCAN data. 
		                        		
		                        			Results:
		                        			In 2022, 282,047 newly diagnosed cancer cases (age-standardized rate [ASR], 287.0 per 100,000) and 83,378 deaths from cancer (ASR, 65.7 per 100,000) were reported. The proportion of localized-stage cancers increased from 45.6% in 2005 to 50.9% in 2022. Stomach, colorectal, and breast cancer showed increased localized-stage diagnoses by 18.1, 18.5, and 9.9 percentage points, respectively. Compared to 2001-2005, the 5-year relative survival (2018-2022) increased by 20.4 percentage points for stomach cancer, 7.6 for colorectal cancer, and 5.6 for breast cancer. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence (M/I) ratios for these cancers. The 5-year relative survival (2018-2022) was 72.9%, contributing to over 2.59 million prevalent cases in 2022. 
		                        		
		                        			Conclusion
		                        			Since the launch of the National Cancer Screening Program in 2002, early detection has improved, increasing the diagnosis of localized-stage cancers and survival rates. Korea recorded the lowest M/I ratio among major comparison countries, demonstrating the effectiveness of its National Cancer Control Program. 
		                        		
		                        		
		                        		
		                        	
5.Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study
Yoon Seok CHOI ; Joonho SHIM ; Ka-Won KANG ; Sang Eun YOON ; Jun Sik HONG ; Sung Nam LIM ; Ho-Young YHIM ; Jung Hye KWON ; Gyeong-Won LEE ; Deok-Hwan YANG ; Sung Yong OH ; Ho-Jin SHIN ; Hyeon-Seok EOM ; Dok Hyun YOON ; Hong Ghi LEE ; Seong Hyun JEONG ; Won Seog KIM ; Seok Jin KIM
Cancer Research and Treatment 2025;57(1):267-279
		                        		
		                        			 Purpose:
		                        			This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea. 
		                        		
		                        			Materials and Methods:
		                        			Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response. 
		                        		
		                        			Results:
		                        			Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression. 
		                        		
		                        			Conclusion
		                        			This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles. 
		                        		
		                        		
		                        		
		                        	
6.Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
Yoon Jung JANG ; Yun Jung YANG ; Hoi Jung KOO ; Hye Won YOON ; Seongbeom UHM ; Sun Young KIM ; Jeong Eun KIM ; Jin Won HUH ; Tae Won KIM ; Seyoung SEO
Cancer Research and Treatment 2025;57(1):280-288
		                        		
		                        			 Purpose:
		                        			In Korea, the Act on Hospice and Palliative Care and Decisions on Life-Sustaining Treatment (LST) was implemented on February 4, 2018. We aimed to investigate relevant factors and clinical changes associated with LST decisions after law enforcement. 
		                        		
		                        			Materials and Methods:
		                        			This single-center retrospective study included patients who completed LST documents using legal forms at Asan Medical Center from February 5, 2018, to June 30, 2020. 
		                        		
		                        			Results:
		                        			5,896 patients completed LST documents, of which 2,704 (45.8%) signed the documents in person, while family members of 3,192 (54%) wrote the documents on behalf of the patients. Comparing first year and following year of implementation of the act, the self-documentation rate increased (43.9% to 47.2%, p=0.014). Moreover, the number of LST decisions made during or after intensive care unit admission decreased (37.8% vs. 35.2%, p=0.045), and the completion rate of LST documents during chemotherapy increased (6.6% vs. 8.9%, p=0.001). In multivariate analysis, age < 65 (odds ratio [OR], 1.724; 95% confidence interval [CI], 1.538 to 1.933; p < 0.001), unmarried status (OR, 1.309; 95% CI, 1.097 to 1.561; p=0.003), palliative care consultation (OR, 1.538; 95% CI, 1.340 to 1.765; p < 0.001), malignancy (OR, 1.864; 95% CI, 1.628 to 2.133; p < 0.001), and changes in timing on the first year versus following year (OR, 1.124; 95% CI, 1.003 to 1.260; p=0.045) were related to a higher self-documentation rate. 
		                        		
		                        			Conclusion
		                        			Age < 65 years, unmarried status, malignancy, and referral to a palliative care team were associated with patients making LST decisions themselves. Furthermore, the subject and timing of LST decisions have changed with the LST act. 
		                        		
		                        		
		                        		
		                        	
7.Epidemiological characteristics of patients with scabies at a Korean university hospital: a single-center retrospective study
Hye Eun HWANG ; Jae Sim JEONG ; Yang Ree KIM ; Ji young LEE
Journal of Korean Biological Nursing Science 2025;27(1):133-143
		                        		
		                        			
		                        			 This study aimed to establish infection control strategies for preventing the spread of scabies within a single institution by analyzing the epidemiological characteristics of patients diagnosed with scabies. Methods: This was a retrospective descriptive study. The electronic medical records of 430 patients diagnosed with scabies at the dermatology outpatient department of Uijeongbu St. Mary’s Hospital from January 2020 to December 2022 were used to collect data on their characteristics. The subjects were divided into three groups: patients, family of confirmed patients, and healthcare workers. General and epidemiological characteristics were analyzed. Results: The average age was 60.89 ± 22.39 years. The number of days from symptom onset to diagnosis was unknown in many cases (65.3%), although the average was 63.42 ± 64.18 days. Repeated visits after treatment were observed in 193 patients (67.5%), 38 family members of confirmed patients (55.1%), and 35 healthcare workers (46.7%), showing a statistically significant difference (p = .002). The most common place of residence before the visit was home (56.2%), and the most common suspected origin of contagion was the home (38.3%), and the most common category of the suspected contagious person was family (49.6%). Conclusion: Cases of scabies were disproportionately common in women and older adults. The interval from symptom onset to diagnosis was long, and about half of the cases involved itching but no skin lesions. More than one-thirds of cases did not revisit for a follow-up after 2 weeks. In the overall results, unlike previous studies, factors related to home and family were frequently observed as epidemiological characteristics. 
		                        		
		                        		
		                        		
		                        	
8.Eligibility for Lecanemab Treatment in the Republic of Korea:Real-World Data From Memory Clinics
Sung Hoon KANG ; Jee Hyang JEONG ; Jung-Min PYUN ; Geon Ha KIM ; Young Ho PARK ; YongSoo SHIM ; Seong-Ho KOH ; Chi-Hun KIM ; Young Chul YOUN ; Dong Won YANG ; Hyuk-je LEE ; Han LEE ; Dain KIM ; Kyunghwa SUN ; So Young MOON ; Kee Hyung PARK ; Seong Hye CHOI
Journal of Clinical Neurology 2025;21(3):182-189
		                        		
		                        			 Background:
		                        			and Purpose We aimed to determine the proportion of Korean patients with early Alzheimer’s disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment. 
		                        		
		                        			Methods:
		                        			We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study. 
		                        		
		                        			Results:
		                        			When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22. 
		                        		
		                        			Conclusions
		                        			Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education. 
		                        		
		                        		
		                        		
		                        	
9.Erratum: Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2023
Dong Jin KIM ; Jeong Ho SONG ; Ji-Hyeon PARK ; Sojung KIM ; Sin Hye PARK ; Cheol Min SHIN ; Yoonjin KWAK ; Kyunghye BANG ; Chung-sik GONG ; Sung Eun OH ; Yoo Min KIM ; Young Suk PARK ; Jeesun KIM ; Ji Eun JUNG ; Mi Ran JUNG ; Bang Wool EOM ; Ki Bum PARK ; Jae Hun CHUNG ; Sang-Il LEE ; Young-Gil SON ; Dae Hoon KIM ; Sang Hyuk SEO ; Sejin LEE ; Won Jun SEO ; Dong Jin PARK ; Yoonhong KIM ; Jin-Jo KIM ; Ki Bum PARK ; In CHO ; Hye Seong AHN ; Sung Jin OH ; Ju-Hee LEE ; Hayemin LEE ; Seong Chan GONG ; Changin CHOI ; Ji-Ho PARK ; Eun Young KIM ; Chang Min LEE ; Jong Hyuk YUN ; Seung Jong OH ; Eunju LEE ; Seong-A JEONG ; Jung-Min BAE ; Jae-Seok MIN ; Hyun-dong CHAE ; Sung Gon KIM ; Daegeun PARK ; Dong Baek KANG ; Hogoon KIM ; Seung Soo LEE ; Sung Il CHOI ; Seong Ho HWANG ; Su-Mi KIM ; Moon Soo LEE ; Sang Hyun KIM ; Sang-Ho JEONG ; Yusung YANG ; Yonghae BAIK ; Sang Soo EOM ; Inho JEONG ; Yoon Ju JUNG ; Jong-Min PARK ; Jin Won LEE ; Jungjai PARK ; Ki Han KIM ; Kyung-Goo LEE ; Jeongyeon LEE ; Seongil OH ; Ji Hun PARK ; Jong Won KIM ;
Journal of Gastric Cancer 2025;25(2):400-402
		                        		
		                        		
		                        		
		                        	
10.Prospective Multicenter Observational Study on Postoperative Quality of Life According to Type of Gastrectomy for Gastric Cancer
Sung Eun OH ; Yun-Suhk SUH ; Ji Yeong AN ; Keun Won RYU ; In CHO ; Sung Geun KIM ; Ji-Ho PARK ; Hoon HUR ; Hyung-Ho KIM ; Sang-Hoon AHN ; Sun-Hwi HWANG ; Hong Man YOON ; Ki Bum PARK ; Hyoung-Il KIM ; In Gyu KWON ; Han-Kwang YANG ; Byoung-Jo SUH ; Sang-Ho JEONG ; Tae-Han KIM ; Oh Kyoung KWON ; Hye Seong AHN ; Ji Yeon PARK ; Ki Young YOON ; Myoung Won SON ; Seong-Ho KONG ; Young-Gil SON ; Geum Jong SONG ; Jong Hyuk YUN ; Jung-Min BAE ; Do Joong PARK ; Sol LEE ; Jun-Young YANG ; Kyung Won SEO ; You-Jin JANG ; So Hyun KANG ; Bang Wool EOM ; Joongyub LEE ; Hyuk-Joon LEE ;
Journal of Gastric Cancer 2025;25(2):382-399
		                        		
		                        			 Purpose:
		                        			This study evaluated the postoperative quality of life (QoL) after various types of gastrectomy for gastric cancer. 
		                        		
		                        			Materials and Methods:
		                        			A multicenter prospective observational study was conducted in Korea using the Korean Quality of Life in Stomach Cancer Patients Study (KOQUSS)-40, a new QoL assessment tool focusing on postgastrectomy syndrome. Overall, 496 patients with gastric cancer were enrolled, and QoL was assessed at 5 time points: preoperatively and at 1, 3, 6, and 12 months after surgery. 
		                        		
		                        			Results:
		                        			Distal gastrectomy (DG) and pylorus-preserving gastrectomy (PPG) showed significantly better outcomes than total gastrectomy (TG) and proximal gastrectomy (PG) with regard to total score, indigestion, and dysphagia. DG, PPG, and TG also showed significantly better outcomes than PG in terms of dumping syndrome and worry about cancer. Postoperative QoL did not differ significantly according to anastomosis type in DG, except for Billroth I anastomosis, which achieved better bowel habit change scores than the others. No domains differed significantly when comparing double tract reconstruction and esophagogastrostomy after PG. The total QoL score correlated significantly with postoperative body weight loss (more than 10%) and extent of resection (P<0.05 for both).Reflux as assessed by KOQUSS-40 did not correlate significantly with reflux observed on gastroscopy 1 year postoperatively (P=0.064). 
		                        		
		                        			Conclusions
		                        			Our prospective observation using KOQUSS-40 revealed that DG and PPG lead to better QoL than TG and PG. Further study is needed to compare postoperative QoL according to anastomosis type in DG and PG. 
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail